Friday, October 25, 2019


Hi! Long time no see :)

This post is on Denosumab!

- Monoclonal antibody against the receptor activator of nuclear factor κB ligand (RANKL)
- Reduces bone resorption by inhibiting the development of osteoclasts

Route: SC
Dosing: Administered twice yearly

Adverse effects:
- Hypocalcemia if vitamin D deficient
- Increased rate of cellulitis and bronchitis
- Osteonecrosis of the jaw
- Atypical femur fracture

- Expensive
- Should be continued indefinitely (discontinuation results in loss of BMD and has been associated with an increased risk of vertebral fracture)
- Safely in CKD (KDIGO stage G3b and G4)
- Preferred if poor adherence or tolerance of oral bisphosphonates

- IkaN

No comments:

Post a Comment

This is express yourself space. Where you type create something beautiful! <3
Wondering what do I write? Well...
Tell us something you know better. You are a brilliant mind. Yes, you are! ^__^
Ask about something you don't understand @_@?
Compliment... Say something nice! =D
Be a good critic and correct us if something went wrong :|
Go ahead. Comment all you like here! (:

PS: We have moderated comments to reduce spam. ALL comments that are not spam will be published on the website.